UroGen Pharma Ltd. (URGN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
UroGen Pharma’s revenue went from $18M in fiscal 2016 to $110M in fiscal 2025, growth of about 22.6% a year.
Net income in fiscal 2025 was -$153M, a net margin of -139.8%; the best year in this period was 2016 with -$2M.
Over the twelve months to September 30, 2026, revenue was $250M and net income -$66M.
Free cash flow was -$163M in fiscal 2025 and positive in 1 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $250M | $110M | $90M | $83M | $64M | $48M | $12M | $18000 | $1M | $8M | $18M |
| Gross profit | $229M | $97M | $82M | $73M | $57M | $43M | $11M | $18000 | -$675000 | $8M | $18M |
| Operating income | -$31M | -$125M | -$97M | -$66M | -$79M | -$92M | -$127M | -$109M | -$77M | -$20M | $798000 |
| Net income | -$66M | -$153M | -$127M | -$102M | -$110M | -$111M | -$128M | -$105M | -$76M | -$20M | -$2M |
| EPS (diluted) | $-1.31 | $-3.13 | $-2.59 | $-2.08 | $-2.24 | $-2.26 | $-2.62 | $-2.14 | $-1.54 | $-0.41 | $-0.04 |
| R&D | $73M | $67M | $57M | $46M | $53M | $48M | $47M | $49M | $37M | $19M | — |
| Revenue growth | — | +21.4% | +9.3% | +28.5% | +34.0% | +307.2% | +65450.0% | −98.4% | −86.2% | −53.5% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$132M | -$162M | -$97M | -$76M | -$88M | -$85M | -$106M | -$71M | -$37M | -$10M | $4M |
| Capital spending | -$203000 | -$289000 | -$295000 | -$194000 | -$254000 | -$752000 | -$1M | -$325000 | -$560000 | -$271000 | -$695000 |
| Free cash flow | -$132M | -$163M | -$97M | -$77M | -$88M | -$86M | -$107M | -$71M | -$38M | -$10M | $3M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $19M | $12M | $13M | $9M | $11M | $23M | $28M | $30M | $31M | $6M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $160M | $283M | $151M | $100M | $89M | $102M | $147M | $101M | $73M | $21M |
| Debt | — | $128M | $123M | $100M | $100M | $1M | $3M | $4M | $3M | — | — |
| Equity | — | -$105M | -$9M | -$65M | -$89M | $8M | $96M | $180M | $90M | $69M | $16M |
| Total assets | — | $200M | $286M | $178M | $136M | $120M | $122M | $202M | $104M | $76M | $23M |
| Shares (diluted) | 50M | 49M | 49M | 49M | 49M | 49M | 49M | 49M | 49M | 49M | 49M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 91.4% | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.5% | 100.0% | -59.8% | 92.7% | 99.8% |
| Operating margin | -12.4% | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1074.2% | -608200.0% | -6842.2% | -244.6% | 4.5% |
| Net margin | -26.3% | -139.8% | -140.3% | -123.6% | -170.6% | -230.7% | -1088.9% | -584100.0% | -6707.2% | -245.2% | -11.1% |
| FCF margin | -52.8% | -148.2% | -107.4% | -92.6% | -136.5% | -178.3% | -907.7% | -396300.0% | -3359.4% | -120.6% | 19.9% |
| ROIC | — | -435.4% | -67.2% | -147.9% | -583.4% | -736.5% | -101.1% | -46.9% | -65.2% | -23.0% | 3.9% |
| ROE | — | 145.5% | 1441.3% | 156.8% | 122.8% | -1317.2% | -133.3% | -58.3% | -84.0% | -29.2% | -11.9% |
Frequently asked questions
What is UroGen Pharma’s annual revenue?
$110M in fiscal 2025 and $250M over the twelve months to September 30, 2026.
How much profit does UroGen Pharma make?
Net income was -$153M in fiscal 2025 (net margin -139.8%).
Is UroGen Pharma’s revenue growing?
Yes: revenue rose 21.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.